Summary The purpose of this study was to assess the usefulness of ultrasonography (US) in the assessment of the breast following primary medical therapy (PMT) of large operable breast cancer. A total of 52 patients were studied; all had invasive breast cancer, confirmed by core biopsy, with initial size > 4 cm by palpation, T2-3, NO-1, MO. PMT was with epirubicin, cisplatin and continuous infusional 5-fluorouracil, as previously described (Jones et al, 1994 , J Clin Oncol 12: 1259-1265. Independent clinical and US assessments were made during PMT before surgery or biopsy. A total of 31 (60%) patients achieved complete clinical response (cCR), but in only five of these was the posttreatment ultrasound normal. Post-treatment sonographic findings of diffuse parenchymal distortion or a mass lesion without Doppler signal were associated with more favourable histology (pathological CR, non-invasive or microinvasive carcinoma), whereas a mass with Doppler positivity was more often associated with residual macroscopic invasive carcinoma. Patients who did not achieve cCR had a high incidence of residual macroscopic carcinoma (71 %) regardless of the sonographic characteristics. With median follow-up of 27 months (range 12-43), ten (19%) patients have relapsed and six (12%) have died, but only one relapse has occurred within treated breast. Ultrasonography is a sensitive technique for assessing the response to PMT, particularly in patients who achieve cCR. It may be helpful in selecting those patients who do not require post-PMT surgery and in localizing abnormalities in those who do, particularly in those with cCR. However, clinicians should be aware that a residual US abnormality is by no means pathognomonic of residual cancer.
The current standard management of a patient with large operable breast cancer is immediate mastectomy followed by adjuvant medical therapy. As an alternative, several groups are investigating primary medical (or 'neoadjuvant') therapy (PMT): immediate drug therapy with surgery deferred until later (Bonadonna et al, 1990; Fisher et al, 1994; Smith et al 1995; Powles et al, 1995) . Reversal of the conventional sequence of treatments may have several potential advantages, including regression of the primary tumour and a reduced need for subsequent mastectomy (Powles et al, 1995; Smith et al, 1995) . High response rates, with complete clinical remission rates of up to 60%, can be achieved even in large primary cancers by the use of moderately dose-intensive infusionbased chemotherapy regimens not requiring growth factor or progenitor cell support (Smith et al, 1995) .
After PMT a decision must be made about the extent, if any, of surgery to be recommended. Here, opinions and policies vary widely. In the recent USA National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 trial of primary chemotherapy, the extent of surgery was left to the discretion of the treating surgeon: 19% of patients who had achieved clinical CR, and 39% of those with partial response (PR), still underwent mastectomy, whereas 50% of those with no change or progressive disease had breastconserving operations (Fisher et al, 1994) . In other series, patients who have achieved clinical CR are treated with radiotherapy alone (Smith et al, 1995) , whereas others have omitted surgery even in patients with only partial response after primary chemotherapy, deferring the decision until after radiotherapy (Weil et al, 1995) .
The final arbiter of these approaches will be the eventual rate of uncontrolled local recurrence -a late end point requiring several years of follow-up. Meanwhile, one logical approach is to assess as accurately as possible the extent of residual disease at the completion of chemotherapy and to base decisions upon that assessment.
Methods of assessment of response to therapy other than clinical examination include mammography and ultrasound. Baseline mammography provides initial information about the presence and extent of malignant calcification and also the presence of multifocal or contralateral carcinoma. However, as a method for assessing response to PMT it is less useful, as continuing mammographic density and calcification are common and correlate poorly with pathological findings (Moskovic et al, 1993) .
Ultrasound is fast, safe, widely available and inexpensive. With the introduction of high-frequency, high-resolution transducers it has become an effective and increasingly used method for the primary assessment and follow-up of breast cancer (Balu-Maestro et al, 1991; Forouhi et al 1994; Tohno et al, 1994; Gawne-Cain et al, 1995) . In addition, various workers have recently described the use of colour Doppler ultrasonography as an adjunct in the diagnosis of breast cancer by detecting malignant neovascularity both in the primary tumour and in axillary lymphadenopathy (Castagnone et al, 1993; Grishke et al, 1994; Kedar et al, 1994; Walsh et al, 1994) . All these features make serial ultrasound scanning a useful method of monitoring response to chemotherapy, but the interpretation of residual sonographic abnormalities after treatment remains uncertain. Accordingly, this study was undertaken to determine the role of ultrasound in monitoring response to primary, in particular, to 
Treatment and assessment protocol
In all cases, the diagnosis of invasive carcinoma was confirmed by core-cut needle biopsy before initiating treatment. PMT consisted of epirubicin, cisplatin and protracted infusional 5-fluorouracil (ECisF) as previously described (Jones et al, 1994; Smith et al, 1995) , for 6-8 cycles of 21 days. In brief, this regimen comprises epirubicin 50-60 mg m-2 and cisplatin 60 mg m-2 on day 1, with continuous ambulatory venous infusion of 5-fluorouracil 200 mg m-2 per 24 h throughout the cycle (days 1-21).
Bidimensional estimation of tumour size was made by a senior clinician using callipers before each cycle of chemotherapy (i.e.
3-weekly) and at the end of treatment. Ultrasonography was performed before treatment and 6-weekly thereafter. Although these assessments were not formally 'blinded', clinical assessments were routinely performed without knowledge of that day's ultrasound result and vice versa. Mammography was performed before treatment but, after work within the unit that showed little value of serial mammography in this circumstance (Moskovic et al, 1992) , serial and post-treatment mammography were not routinely performed.
After primary medical therapy, patients were treated according to the residual abnormality. Those with no palpable abnormality were eligible to be treated with radiotherapy alone, although in most cases if a residual area of abnormality was detectable on ultrasound this was first widely excised under US-guided needle localization, or biopsied with multiple core-cut biopsies. Those with a residual palpable abnormality were subjected to either breast-conserving surgery or mastectomy according to the normal surgical criteria of size and position. Patients undergoing breast surgery also had level 2 axillary dissection.
All patients who had not undergone mastectomy received radiotherapy to the residual breast tissue. Those who had not had axillary dissection also received radiotherapy to the axilla. Other nodal areas were not routinely irradiated. All patients regardless of age, menstrual status and hormone receptor status received adjuvant tamoxifen 20 mg o.d. for 2 years from completion of chemotherapy.
Ultrasound technique
Patients were scanned using a 7-MHz hand-held linear array transducer attached to an Acuson 128 computed sonography unit (Mountain View, CA, USA). Measurements of the tumour size (cm) in three orthogonal planes were obtained using real-time ultrasound and then the mass was assessed for colour Doppler signals. The Acuson capability for colour Doppler (5 MHz) was used for flow evaluation using the standardized machine settings. These settings were chosen to optimize sensitivity to low velocity and low-volume blood flow. Doppler positivity was ascribed if colour Doppler signals were obtained within 5 mm of the margin of the tumour or inside it. In addition, a visual score from 0 to 3 of the vascularity of the tumour provided by the colour Doppler signal was made at each scan.
After therapy, in the case of sonographic resolution of the primary breast tumour, the presence, appearance and measurements of any residual parenchymal distortion are recorded with any associated Doppler signal, if present. 
RESULTS
The clinical and sonographic response rates are shown in Table 2 . The ECisF chemotherapy regimen produced a high clinical CR (cCR) rate of 60%, but ultrasonographic abnormalities remained in the majority of these patients. A consistent finding in the general appearance of the post-treatment breast on ultrasound was the presence of diffusely echogenic tissue at the site of previous tumour and surrounding any residual tumour, which effaced the normal parenchymal echopattern locally. This brightly reflecting tissue appeared to correspond to hyalinized fibrofatty tissue seen pathologically in association with the region of treated tumour. Post-treatment histological findings in 45 patients are shown in Table 3 . Pathological CR (pCR) was found in nine, with a further 14 patients showing abnormalities not amounting to residual invasive tumour masses (scattered atypical cells in five; DCIS in four; microinvasion in five). The remaining 22 patients had residual invasive tumour masses.
The contribution of ultrasound in patients without cCR
Twenty-one patients had palpable abnormalities at the end of treatment. In every case, surgery was performed (wide local excision in 18; mastectomy in three). DCIS alone was found in three, and microinvasion in two. The remaining 16 operative specimens contained residual macroscopic invasive cancers, although in five cases the residual disease was of a lower grade than the pretreatment biopsy.
In all 21 patients with palpable residual disease, a measurable sonographic lesion was also present. However, the ultrasound findings, including Doppler signal, were not helpful in distinguishing those patients with macroscopic invasive cancers from those with lesser histological findings (Table 4) . Nor was ultrasound superior to clinical assessment in predicting the maximum diameter of the excised tumour (data not shown). The contribution of ultrasound in patients with cCR
Of the 31 patients with cCR, 15 underwent US-assisted wide local excision of sonographic abnormalities and nine had multiple USguided core-cut biopsies (seven went on to radiotherapy without biopsy). Histology in these 24 patients showed residual macroscopic invasive cancer in six, microinvasion or scattered suspicious cells in six, DCIS in two, and no evidence of disease in ten. Table 5 shows the ultrasound and histological findings in these women.
The significance of normalization of the ultrasound (uCR) was not determined in this study. This occurred in five patients, but in only one was biopsy undertaken -using multiple core-cut biopsies of the previously affected segment. These showed no evidence of disease. Other patients with uCR proceeded to radiotherapy without biopsy.
In five patients the post-treatment ultrasound showed a residual area of diffuse parenchymal abnormality without Doppler signal. Histological findings in these patients varied from pCR in one patient to scattered degenerate carcinoma cells in three patients, to frank residual carcinoma in one patient. Figure 1 shows representative appearances in a patient with cCR whose post-treatment ultrasound showed diffuse parenchymal distortion. When multiple core-cut biopsies were obtained from this area, they showed microscopic foci of scattered degenerate atypical cells indicating residual carcinoma.
The remaining 21 patients with cCR had measurable residual mass lesions on ultrasound (Table 5 ). The presence of Doppler signal appeared to predict for residual disease in these patients: five out of six patients with Doppler positivity had residual cancer or DCIS on histology. On the other hand, among patients with Doppler-negative mass lesions, 7 out of 12 had pCR.
DISCUSSION
The initial results of primary medical therapy (PMT) for large operable breast cancer are encouraging: the technique appears to enable breast-conserving treatment to be offered to a majority of the women who currently require mastectomy. The early results of our series and others suggest that this is not at the cost of a high rate of local relapse. It is not yet known whether PMT also confers an advantage in terms of long-term systemic control and survival; this question has been addressed in ongoing randomized trials by the NSABP, the EORTC and others. However, even if these trials were to show no overall survival advantage for PMT, the benefits The current working assumption of our unit and others is that, after primary chemotherapy, residual invasive carcinoma, microinvasive carcinoma or carcinoma in situ should be widely resected and the breast subsequently irradiated. Conversely, patients with pathological CR might safely be treated with radiotherapy alone.
However, it is not known whether these assumptions are correct. Treatment of primary DCIS with radiotherapy is an accepted alternative to mastectomy, forming an arm of current trials, and a similar approach might reasonably be considered with noninvasive carcinoma, or even microinvasive carcinoma, after primary chemotherapy.
The use of histological criteria for guiding post-PMT management raises its own problems. In this study, a compromise was reached between the certainty of the histological diagnosis and the demands of breast conservation. For those patients in whom PMT was most effective and the tumour site was no longer easily identifiable after treatment, an extensive resection would have been required for full histological assessment. Instead, we used the approach of more limited sampling with multiple core-cut biopsies, or in some cases no biopsy. Inevitably, this limits the confidence of our histological response rate. Some other centres use skin tattooing or inject carbon or metal markers into the tumour at the start of treatment in order to allow selective biopsy of the area after PMT (Veronesi et al, 1995) .
The potential role of ultrasound in post-chemotherapy assessment is to help select, in cases where there is clinical doubt, those patients who do or do not require excision, and to localize lesions in those who do.
For patients who had a residual palpable tumour or 'thickening' at the end of PMT, we found that US contributed little. All these patients had residual pathological lesions that by our current criteria required excision, although in six cases these did not amount to macroscopic invasive carcinoma. In all cases, sonographic lesions persisted, but the sonographic findings (including Doppler positivity) were not required for localization, did not contribute to the surgical decision and did not identify the patients with only non-invasive or microinvasive residual disease.
In patients with clinical CR (cCR), ultrasound proved a more useful investigation. The majority (84%) of patients with cCR had residual sonographic abnormalities; ultrasound is a useful technique for localization in these patients, but does it predict the pathological findings and identify a group who may not require surgery? Of the 23 such patients who underwent guided excision or biopsy, nine (39%) proved to have pathological CR (pCR) (Kedar et al, 1994) . This and other new refinements in ultrasound technology may be useful for the detection of abnormal low-velocity flow in vessels. A recent report has shown dedicated breast magnetic resonance imaging (RODEO MRI) to be a promising technique for prediction of pathological response to primary chemotherapy (Abraham et al, 1996) , and a comparison of these techniques would be interesting.
The next step in rationalizing decisions about treatment after PMT must involve randomization between different approaches. For example, patients with cCR after PMT could be randomized to have radiotherapy alone or US-guided wide local excision plus radiotherapy. The reference of ultrasound assessment will be determined by long-term follow-up from such randomized trials.
